DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20163202

Empagliflozin: a wonder drug in preventing diabetic nephropathy and cardiovascular effects

Thotakura Naveena

Abstract


Diabetes, a terrible disease, with highest incidence in world produces many complications which will end up in dreadful situations. Diabetes nephropathy is one of the complications which lead to dialysis, renal replacement. empagliflozin, sodium glucose cotransporter 2 inhibitors decreases plasma blood glucose level, HbA1C and weight by excreting glucose in urine. It by decreasing HbA1C results in decrease in complications of diabetes due to high blood sugar and fluctuating blood sugars. It decreases the blood pressure, arterial stiffness and vascular resistance. It decreases the risk factors of diabetic nephropathy like hyperglycemia and high blood pressure. It also decreases the diabetes-related glomerular hypertrophy, markers of renal inflammation, as well as mesangial matrix expansion and thus ameliorates the early signs of diabetic nephropathy. The efficacy in decreasing blood glucose levels was confirmed in four randomized placebo controlled studies. The safety concern was seen in studies were urinary and genital tract infections. It thus proves to be an efficient option for diabetes in preventing diabetes nephropathy and cardiovascular effects.


Keywords


Empagliflozin, Diabetic nephropathy, Diabetes, SGLT2

Full Text:

PDF

References


Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India - the Chennai Urban Rural Epidemiology Study CURES-17. Diabetologia. 2006;49:1175-8.

Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM (ed.) Brenner and rector’s the kidney. 7th ed. Philadelphia, PA: WB Saunders; 2004:1777-818.

Diabetes nephropathy, 2016. Available at https://en.wikipedia.org/wiki/Diabetic_nephropathy. Accessed on 23 July 2016.

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76.

Mogensen CE, Christensen K, Vittinghus E. The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(Supplement 2):64-78.

Zinman B, Wanner C, Lachin JM, Fitchett D. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, Obesity and Metabolism. 2013;15(12):1154-60.

Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. Journal of Diabetes Investigation. 2014;5(3):265-75.

Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin-dependent diabetes. Diabetes. 2005;54:3427-34.

Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovascular Diabetology. 2014;13:28.

Häring HU, Merker L, Becker ES, Weimer M. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. Diabetes Care. 2013;36(11):3396-404.

Häring HU, Merker L, Becker ES, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24- week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-9.

Roden M, Weng J, Eilbracht J. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes and Endocrinology. 2013;1(3): 208-19.

Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2013;15(8):721-8.

Cherney DZ, Perkins BA. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13(28):1475-2840.

Macha S, Dieterich S, Mattheus M, Seman LJ, Broedl UC, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:132-40.

Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther.2012;29:889–899.

Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33-42.

Macha S, Mattheus M, Pinnetti S, Seman L, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. Diabetes Res Clin Metab. 2012;1:1-7.

Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013;15:316-23.

Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35:226-35.

Macha S, Lang B, Pinnetti S. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers. J Diabetes Investig. 2012;3:228.

Macha S, Mattheus M, Pinnetti S. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig. 2013;33:351-7.